Retraction: Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability (PLoS One (2011) 6:3 (e18076) DOI: 10.1371/journal.pone.0018076);Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Cai, Jun ^a   Wu, Lin ^a   Qi, Xiaoping ^a   Shaw, Lynn ^a   Li Calzi, Sergio ^a   Caballero, Sergio ^a   Jiang, Wen G ^b   Vinores, Stanley A ^c   Antonetti, David ^d   Ahmed, Asif ^e   Grant, Maria B ^a   Boulton, Michael E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 1; PLACENTAL GROWTH FACTOR 2; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TYROSINE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; CADHERIN; CLAUDIN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL ACTIVATION; CELL JUNCTION; CELL MEMBRANE; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; VASCULAR ENDOTHELIUM; ANIMAL; CAPILLARY PERMEABILITY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PROTEIN BINDING; TIGHT JUNCTION; TIME; TRANSCRIPTION INITIATION;

ADHERENS JUNCTIONS; ANIMALS; ANTIGENS, CD; BASE SEQUENCE; CADHERINS; CAPILLARY PERMEABILITY; CLAUDINS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PREGNANCY PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TIGHT JUNCTIONS; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79953054278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0210983     Document Type: Erratum

References (54)

1. Dejana E, Tournier-Lasserve E, Weinstein BM, (2009) The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 16: 209-221.
2. Weis SM, (2008) Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol 15: 243-249.
3. Erickson KK, Sundstrom JM, Antonetti DA, (2007) Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10: 103-117.
4. Vestweber D, Winderlich M, Cagna G, Nottebaum AF, (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 19: 8-15.
5. Balda MS, Matter K, (2008) Tight junctions at a glance. J Cell Sci 121: 3677-3682.
6. Fanning AS, Anderson JM, (2009) Zonula occludens-1 and-2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann N Y Acad Sci 1165: 113-120.
7. Gavard J, (2009) Breaking the VE-cadherin bonds. FEBS Lett 583: 1-6.
8. Umeda K, Ikenouchi J, Katahira-Tayama S, Furuse K, Sasaki H, et al. (2006) ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126: 741-754.
9. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, et al. (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-157.
10. Gavard J, Gutkind JS, (2006) VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223-1234.
11. Murakami T, Felinski EA, Antonetti DA, (2009) Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem 284: 21036-21046.
12. Yamazaki Y, Morita T, (2006) Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10: 515-527.
13. Kowanetz M, Ferrara N, (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022.
14. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, et al. (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8: 925-931.
15. Ribatti D, (2008) The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 11: 215-221.
16. DiPalma T, Tucci M, Russo G, Maglione D, Lago CT, et al. (1996) The placenta growth factor gene of the mouse. Mamm Genome 7: 6-12.
17. Autiero M, Luttun A, Tjwa M, Carmeliet P, (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1: 1356-1370.
18. Luttun A, Brusselmans K, Fukao H, Tjwa M, Ueshima S, et al. (2002) Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 295: 428-434.
19. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840.
20. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, et al. (2002) Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 115: 2559-2567.
21. Cao Y, (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2: re1.
22. Cai J, Jiang WG, Grant MB, Boulton M, (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281: 3604-3613.
23. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9: 936-943.
24. Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, et al. (2006) Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 66: 3971-3977.
25. Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, et al. (2003) A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 101: 560-567.
26. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, et al. (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59: 4129-4135.
27. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, et al. (2002) Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 1: 99-108.
28. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
29. Park JE, Chen HH, Winer J, Houck KA, Ferrara N, (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654.
30. Bais C, Wu X, Yao J, Yang S, Crawford Y, et al. (2010) PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141: 166-177.
31. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, et al. (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141: 178-190.
32. Bjorndahl M, Cao R, Eriksson A, Cao Y, (2004) Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ Res 94: 1443-1450.
33. Shih SC, Ju M, Liu N, Smith LE, (2003) Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 112: 50-57.
34. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, et al. (1997) Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 76: 517-531.
35. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF, (2008) Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11: 109-119.
36. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, et al. (2008) Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 10: 923-934.
37. Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, et al. (2008) Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol 172: 521-533.
38. Soma T, Chiba H, Kato-Mori Y, Wada T, Yamashita T, et al. (2004) Thr(207) of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP. Exp Cell Res 300: 202-212.
39. Esteve PO, Chin HG, Pradhan S, (2007) Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282: 2615-2625.
40. Derevjanik NL, Vinores SA, Xiao WH, Mori K, Turon T, et al. (2002) Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43: 2462-2467.
41. Luna JD, Chan CC, Derevjanik NL, Mahlow J, Chiu C, et al. (1997) Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J Neurosci Res 49: 268-280.
42. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, et al. (1998) Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78: 109-116.
43. Cai J, Ahmad S, Jiang WG, Huang J, Kontos CD, et al. (2003) Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52: 2959-2968.
44. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, et al. (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791.
45. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH, (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
46. Mac Gabhann F, Popel AS, (2004) Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 286: H153-164.
47. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, et al. (1998) Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273: 22272-22278.
48. May C, Doody JF, Abdullah R, Balderes P, Xu X, et al. (2005) Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 105: 4337-4344.
49. Gulino D, Delachanal E, Concord E, Genoux Y, Morand B, et al. (1998) Alteration of endothelial cell monolayer integrity triggers resynthesis of vascular endothelium cadherin. J Biol Chem 273: 29786-29793.
50. Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, et al. (2005) The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 24: 2992-3001.
51. Gory S, Dalmon J, Prandini MH, Kortulewski T, de Launoit Y, et al. (1998) Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem 273: 6750-6755.
52. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S, (2006) Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 345: 292-301.
53. Cai J, Jiang WG, Ahmed A, Boulton M, (2006) Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc Res 71: 20-31.
54. Martin TA, Watkins G, Lane J, Jiang WG, (2005) Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 46: 422-430.